Copyright
©The Author(s) 2025.
World J Gastrointest Pharmacol Ther. Mar 5, 2025; 16(1): 103898
Published online Mar 5, 2025. doi: 10.4292/wjgpt.v16.i1.103898
Published online Mar 5, 2025. doi: 10.4292/wjgpt.v16.i1.103898
Table 6 Nature and association of adverse events during the study
| Variables | Frequency | Percentage |
| Nature of adverse event | ||
| Diarrhea | 6 | 26.09 |
| Constipation | 4 | 17.39 |
| Giddiness | 3 | 13.04 |
| Headache | 2 | 8.70 |
| Acidity | 2 | 8.70 |
| Polydipsia | 1 | 4.35 |
| Loose motion | 1 | 4.35 |
| Polyphagia | 1 | 4.35 |
| Fatigue | 1 | 4.35 |
| Dry mouth | 1 | 4.35 |
| Vomiting | 1 | 4.35 |
| Association of adverse events using causality assessment criteria | ||
| Related | 15 | 65.22 |
| Unrelated | 7 | 30.43 |
| Possible | 1 | 4.35 |
- Citation: Lawate P, Chauhan V, Prasad LR, Pawar A, Puranik AG, Bansal A, Koganti A, Jaiswal A, Puradkar P, Jhaveri K. Real-world-evidence, prospective-observational study to evaluate safety and effectiveness of rabeprazole dual-delayed-release capsules in patients with gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther 2025; 16(1): 103898
- URL: https://www.wjgnet.com/2150-5349/full/v16/i1/103898.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v16.i1.103898